The exponential rise in costs despite numerous years of hard work has hampered the proficiency, productivity and efficiency of this research. Nevertheless, due to in silico and computational advances, databanks have accelerated the decoding of genes sequences to 3D complex biomolecules in a very short time span. The important advantage of a computational technique is its ability to eliminate unpromising lines of inquiry early in the discovery process. With the help of the combinatorial library and database mining, it is possible to undertake a specific chemical reaction on various identical reactants in all possible combinations. Chemoinformatics will help to identify promising molecules of greater importance at earlier stages viz., to eliminate failures at the latter stages.
Introduction
Competition and cost has changed the drug design paradigm from the hit and trial approach to the drug design approach allowing the tailormade design of active molecules. This has resulted in both targeted drug discovery and reduced drug development cycle time. The need for introducing newer molecules that are superior using an automated approach will make drug discovery a highly knowledge specific and efficient process. Some of the techniques that are evolved over time are schematically presented in Figure 1 indicating that, progressively, every step in the drug discovery chain has become automated.
Figure 1 Progress in drug discovery with time
The rapid change in global competition, growth in IT and emergence of low cost storage technology have facilitated the paradigm change in drug discovery. Every new drug on the market has its own story to tell as to how it succeeded in surmounting various hurdles beginning from conceptualisation to reality. Knowledge management is playing in a major role in almost all chemical and pharmaceutical companies. New chemoinformatics units are created to assist ongoing drug discovery programs. Many studies have appeared on chemoinformatics. This paper briefly outlines managerial issues and the support required for the effective implementation of chemoinformatics in small as well large organisations successfully. ' 'mixing of information resources to transform data into information, and information into knowledge, intending for better rapid decisions in the arena of drug lead identification and optimisation." [2] Chemoinformatics play a vital link between theoretical design and in drug design through extraction of information from the data and conversion into knowledge (Figure 2 ). Derivation of information and knowledge is only one aspect of chemoinformatics. Chemoinformatics methods can be used proactively to design and filter the most appropriate compounds to work with in the real world. It is worth mentioning the roles of chemical information systems in this context. The use of derived knowledge in a design and selection support role is an important part of the drug design cycle. The main processes within drug discovery are lead identification, where a lead is something that has activity in the low micromolar range, and lead optimisation, which is the process of transforming a lead into a drug candidate. On identifying the molecular target various stages involved in the drug development are depicted in Figure 4 . 
Approach towards chemoinformatics
For the effective implementation of chemoinformatics different firms and organisations follow various approaches which includes compound registration (Database Creation), library enumeration, navigating virtual libraries, access to primary and secondary scientific literature, QSAR (quantitative structure/activity relationships), physicochemical property calculations and integrated chemical structure based property databases [3] . These approaches require tools not only for the analysis of experimental data, but also for the generation of calculated properties of molecules.
Physico-chemical property predictions
For a long time, efforts were directed towards predicting the properties of chemical species (drugs, drug-like candidates, drug-intermediates etc.). However recent advances in chemoinformatics include new molecular descriptors and pharmacophore techniques, statistical tools and their applications. The ability to predict so-called ADME (absorption, distribution, metabolism and excretion) properties from a molecular structure would have a tremendous impact on the drug discovery process both in terms of cost and the amount of time required to bring a new compound to market. Over several years there has been a tremendous shift towards an emphasis on the optimisation of ADME properties early in the life of drug discovery programs.
Two strategies are likely to emerge in the area of physico-chemical property prediction: first to develop a general approach to screen large number of compounds, and then to attempt a high level of accuracy for more diverse compounds. Future research will probably focus on developing models with datasets that are larger and built around more diverse collections of compounds with a wide range of chemical functionalities. The focus is on predicting human pharmacokinetic parameters, human intestinal absorption, LogP, ClogP, local absorption rate, solubility and permeability, reduced ion mobility, drug absorption and transport phenomena. The application of chemoinformatics tools to predict all these physico-chemical properties are reviewed [4] .
In silico generation of virtual molecules
In the present scenario, computational tools play a major role in the design of the libraries prior to synthesis that meet the defined criteria of similarity or diversity. The term in silico is extensively used to describe the virtual world of data, analysis, models and designs within a computer [5, 6] . Rapid identification of a lead compound or a series, remain the primary objective of all high-throughput screening.
The 'real' world of compounds synthesised in a chemical laboratory and tested in a biological laboratory is a small part of a larger 'virtual' world where hypotheses may be computer-generated and practically tested.
To address these, an appropriate structure coding has to be chosen, which is related to the biological activity under investigation. These encoding structural features efficiently play an important role as they work as a fingerprint for similarity analysis [7, 8] . Moreover, the structure-coding scheme must produce the same number of descriptors, irrespective of the size and the number of atoms in a molecule. An interesting example of a new descriptor is the 'feature tree', a novel way of representing the characteristics of a molecule [9] . Work on three-dimensional pharmacophore and shape representations continues, because these are the methods that should mimic a receptor's viewpoint, rather than a chemist's perception of the internal make-up of a molecule [10] .
3D sub-structural descriptors based upon potential pharmacophoric patterns have also been widely used for diversity analysis as have physico-chemical properties that describe a molecule's topological, electronic, steric, lipophilic or geometric features [11] [12] [13] [14] [15] .
The library enumeration where the core sub-structures are identified as templates with few atoms will be left open for substituents (R-groups). By varying the R-groups at the points of substitution different product structures can be generated. Rebek et al. [16] published the synthesis of two combinatorial libraries of semi-rigid compounds that were prepared by condensing a rigid central molecule functionalised by four acid chloride groups with a set of 19 different L-amino acids.
The more symmetric skeleton give fewer compounds as shown in Figure 5 . However if the core sub-structure contains symmetric geometry it may create duplicate structures during enumeration. This problem could be overcome by implementing a similarity check algorithm based on the connection table and chirality of the atoms involved. Estimates of the number of drug-like compounds that could theoretically be made are greater than 1040 [17] . Deciding which of these molecules to synthesise and test require a good decision support system. Four principal types of selection procedures are cited in the literature based on cluster, partition, dissimilarity and optimisation. For the datasets studied, Bayada et al., concluded that Ward's clustering of two-dimensional fingerprints gave the biggest improvement over random selections while in a different study, the use of a partitioned chemical descriptor space showed how such a space could be used for diverse subset selections [18] . The latter method obviates the problem of some clustering techniques, where the clusters change as new molecules are added in a study. The above methods allow the calculated property profile of a virtual library to be optimised so that it most effectively matches a desired target, such as the properties of a collection of drug-like molecules. They can also cope with the huge combinatorial space that must be examined when selecting monomers for a library that is to be smaller than that theoretically possible. Few useful papers have appeared on library design methods [19] [20] [21] . Experience has shown that library design should preferably be based on calculated properties in product space rather than in monomer space [22] .
Synthetic chemists favour software systems based on chemical transformations that mimic the actual chemistry carried out as these are more familiar [23, 24] . Alternative methods that require the identification of the common core and appended fragments of a library [25, 26] are faster once the separate parts of the product have been defined, but this often requires considerable human intervention. Hybrid systems have also been developed [26, 27] .
Strategies for more efficient biological screening continue to evolve. Rather than relying on very large screening campaigns, iterative screening strategies are being explored. These involve screening smaller, selected sets of molecules and using the derived results to define descriptors for the rational selection of a further set of molecules. While this obviously mimics the traditional medicinal chemistry approach of responding to new data, it has taken some time for it to be effectively translated into the library paradigm. Statistical tools such as recursive partitioning [28] can assist in this process to identify which descriptors about a lead should be pursued.
Alternative approaches are where the actual reaction is simulated through a synthetic knowledge base. This more closely replicates the stages involved in the actual synthesis, in which reagents should react together according to the rules of synthetic chemistry. A strong background in the Computer Aided Organic Synthesis (CAOS) program will help to generate reasonable structures of synthetic importance. So far more attention has been paid to the generation of descriptors for diversity analysis than studies on fragment substructures or physico-chemical properties [29] .
Role of natural product chemistry in chemoinformatics
A natural product is an important sector in the area of drug discovery and development. Most encouraging is the continuing emergence of new natural product chemotypes with interesting structures and biological activities and potential for sub-library generation of targeted screening. Increasingly available as pure compounds, natural products are highly amenable to the much broader screening opportunities presented by the new targets. Regardless of chemical library input, natural products are uniquely well placed to provide structural information from which virtual compounds can be created by computational chemistry and allied technologies. The structural versatility of natural products is expected to play a major role in modern drug discovery programs [30] .
Review of drug company status (growth sector)
The major companies are using chemoinformatics in an integrated manner for areas that have high growth potential. The challenge is to learn rapidly how to leverage chemoinformatics to bring newer molecules that have highly predictable activity characteristics to minimise time and clinical trial costs. Genomics, proteomics and chemoinformatics will increase the diffusion of IT into the pharmaceutical industry. This will require a higher level organisational knowledge integration process that was hitherto non-existent in the pharmaceutical industry. Drug discovery is moving into the realm of IT. Structural knowledge and drug knowledge is getting highly integrated. In recent years organisations have been focusing on the knowledge based drug design as shown in Figure 6 . Major pharmaceutical organisations with a large database backbone and vast experience in this field will concentrate on structure based design whereas newly created organisations with zero knowledge will try for random screening in the early stages. 
Organisational structures for implementation
Chemoinformatics has evolved through individual initiatives of many firms. IT and drug discovery are distinct competences in the existing organisational environment and hence will require coordination. The success of leveraging chemoinformatics will depend on the ability of firms to use chemoinformatics to reduce the drug discovery cycle and the ability to integrate chemoinformatics into the organisational knowledge creation process. The main organisational issue is managing the IT and the drug discovery process. Organisations have two options for sourcing chemoinformatics competence through 1 in-house facilities and 2 outsourcers.
The way chemoinformatics is developing may enable firms to outsource it, as it is a specialised competence. The difficulty in getting specialised experts on chemical information is likely to be compounded in the future.
Identifying partners
The major issue in leveraging chemoinformatics is identifying competent partners without losing competitive edge and at the same time creating new molecules of medicinal importance. Selecting 'representative' molecules from clusters created in a multidimensional chemical descriptor space often requires the selection of subsets of molecules for screening. Computational library design techniques using genetic algorithms [31, 32] have become vital because of the need to design more efficient libraries.
Tools and techniques
With the advent of client/server concepts of computing and the deep penetration of WEB technologies into most computing environments, however, the situation is rapidly changing. Software and hardware application systems have emerged and now they are becoming integrated. Since growth is not organic if the applications have to catch up there has to be a major drive towards standardisation. Use of the web is widely accepted for text and image handling, utilising scientific tools is technically more difficult. Many of the tools developed and applied in chemoinformatics by various software vendors [33] [34] [35] [36] [37] [38] [39] . While tools for making chemoinformatics methods more accessible to bench scientists are important, the receptiveness of medicinal chemists to these techniques requires that their training in statistics, data analysis, visualisation and biomolecular concepts be improved. The interest shown in Lipinski's 'rule of five' [40] , which succinctly encapsulates some simple parameters concerning drug absorption, shows how eager medicinal chemists are for rules to help design appropriate molecules in the libraries era. This illustrates a real need for both better end-user tools and training of chemists, biologists and interdisciplinary experts to apply the more advanced methods effectively. A list of databases available from different sources is presented in Table 1 . From the Table it is clear that if every organisation collects and generates its own library, there will be repetition of information. There must be a mechanism or tool to be developed to link all the related information. This will help to develop a unique database with a global interest and one point access to chemical information. Some of the key players in this area are listed in Table 2 . 
Technical issues
Chemoinformatics software from software houses is expensive. Building and maintaining your own solutions is also expensive. Thus, for good tools and knowledge, one must be prepared to commit significant resources in this area, in terms of hardware, software and people-ware (i.e. effective creators and users of software). Avoiding supplier monopolies and looking for cheaper modules to be substituted for outdated or overpriced parts helps keep costs down. This, however, requires software to be assembled in a modular fashion in the first place and to be mutually compatible. Structure representation on a computer in an encoded form is an almost matured field now, however many organisations follow their own file format for storage of structure in addition to their in-house acquired research data. Much time will continue to be wasted with incompatible file types without internationally agreed standards. There is a need to develop a compact unicode for individual molecules along with a structural descriptor, which should be implemented in all the databases available globally as a linking medium, irrespective of database type in the e-world. All the compounds, including the virtual library of molecules, should be referred to using this unicode comparable with the registry number of individual compounds by a chemical abstract service or Beilstein etc., This unicode technique will reduce duplication of information.
Current status
Recent advances in virtual screening track computational capability and as the processing power of computers improves, so do screening speed and complexity. Parameters such as structure, function or chemical space allow for a nearly limitless array of screening options. The use of screening data for development decision making is predicated from the management and interpretation of the data. Extraction of information from the data is the vital link between theoretical design and the drug candidate. Finally, it is the integration of iterative results from computation to activity that drives the cycle forward. Library chemistry and high-throughput screening require the greater use of chemoinformatics to increase their effectiveness. However to identify types of procedure which yield the best result and address factors such as cost, availability and synthetic feasibility rest with the user's decision. In parallel, another area that is gaining greater importance, is the development of filtering procedures which identifies molecules that exhibit some sort of undesirable characteristic (toxicity, high reactivity etc.). Combinatorial chemistry has opened up new strategies for a more comprehensive parallel approach to sweeping and searching during lead optimisation, which has necessitated the development of suitable and new library design principles.
Conclusions
The explosion of raw data coming from library synthesis and HTS operations has driven the need for an improved chemoinformatics systems. In the first instance knowledge gained by analysis of data is as good as the quality of the data. However, the increase in the amount of data available is often at the expense of context and quality. The next phase of the challenge could be to have quality chemoinformatics tools to apply to quality data. At least we may achieve something other than a new name for a continuing problem. This integration of chemical information and drug discovery will completely change the drug discovery process, allowing small and innovative firms to be active in drug discovery. 
